Role of ferroptosis in hepatocellular carcinoma

Journal of Cancer Research and Clinical Oncology

Volumn 144, Issue 12, 2018, Pages 2329-2337

  Nie, Jianhua ^a   Lin, Binlin ^a   Zhou, Meng ^a   Wu, Li ^a   Zheng, Tongsen ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Ferroptosis; Hepatocellular carcinoma; Iron; Lipid metabolism; Sorafenib; Therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CDGSH IRON SULFUR DOMAIN 1; DOCOSAHEXAENOIC ACID; ERASTIN; HALOPERIDOL; LOW DENSITY LIPOPROTEIN; NANOPARTICLE; PEPTIDES AND PROTEINS; PROTEIN P53; RETINOBLASTOMA PROTEIN; SORAFENIB; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

DRUG EFFICACY; DRUG MECHANISM; DRUG RESISTANCE; FERROPTOSIS; GENETIC POLYMORPHISM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIPID METABOLISM; LIVER CELL CARCINOMA; PRIORITY JOURNAL; REVIEW; ANIMAL; CARCINOGENESIS; CELL DEATH; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC VARIATION; GENETICS; LIVER TUMOR; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CELL DEATH; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VARIATION; HUMANS; LIPID METABOLISM; LIVER NEOPLASMS; SIGNAL TRANSDUCTION; SORAFENIB;

EID: 85053269521     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-018-2740-3     Document Type: Review

References (55)

1. Alvarez SW et al (2017) NFS1 undergoes positive selection in lung tumours and protects cells from ferroptosis. Nature 551:639–643. 10.1038/nature24637
2. Arlt A et al (2013) Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity. Oncogene 32:4825–4835. 10.1038/onc.2012.493
3. Bai T, Wang S, Zhao Y, Zhu R, Wang W, Sun Y (2017) Haloperidol, a sigma receptor 1 antagonist, promotes ferroptosis in hepatocellular carcinoma cells. Biochem Biophys Res Commun 491:919–925. 10.1016/j.bbrc.2017.07.136
4. Bruix J et al (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London England) 389:56–66. 10.1016/s0140-6736(16)32453-9
5. Chen WC, Wang CY, Hung YH, Weng TY, Yen MC, Lai MD (2016) Systematic analysis of gene expression alterations and clinical outcomes for long-chain acyl-coenzyme a synthetase family in cancer. PloS One 11:e0155660. 10.1371/journal.pone.0155660
6. Cheng AL et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34. 10.1016/s1470-2045(08)70285-7
7. Dixon SJ et al (2012) Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149:1060–1072. 10.1016/j.cell.2012.03.042
8. Dixon SJ et al (2014) Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress ferroptosis. Elife 3:e02523. 10.7554/eLife.02523
9. Do Van B et al (2016) Ferroptosis, a newly characterized form of cell death in Parkinson’s disease that is regulated by PKC. Neurobiol Dis 94:169–178. 10.1016/j.nbd.2016.05.011
10. Eling N, Reuter L, Hazin J, Hamacher-Brady A, Brady NR (2015) Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. Oncoscience 2:517–532. 10.18632/oncoscience.160
11. Firestone RA (1994) Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. Bioconj Chem 5:105–113
12. Friedmann Angeli JP et al (2014) Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol 16:1180–1191. 10.1038/ncb3064
13. Galmiche A, Chauffert B, Barbare JC (2014) New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma. Cancer Lett 346:159–162. 10.1016/j.canlet.2013.12.028
14. Guo J et al (2018) Ferroptosis: a novel anti-tumor action for cisplatin. Cancer Res Treat 50:445–460. 10.4143/crt.2016.572
15. Hambright WS, Fonseca RS, Chen L, Na R, Ran Q (2017) Ablation of ferroptosis regulator glutathione peroxidase 4 in forebrain neurons promotes cognitive impairment and neurodegeneration. Redox Biol 12:8–17 10.1016/j.redox.2017.01.021
16. Hao S et al (2017) Cysteine dioxygenase 1 mediates erastin-induced ferroptosis in human gastric cancer cells. Neoplasia (New York NY) 19:1022–1032. 10.1016/j.neo.2017.10.005
17. Harrison PM, Arosio P (1996) The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1275:161–203
18. Hayano M, Yang WS, Corn CK, Pagano NC, Stockwell BR (2016) Loss of cysteinyl-tRNA synthetase (CARS) induces the transsulfuration pathway and inhibits ferroptosis induced by cystine deprivation. Cell Death Diff 23:270–278. 10.1038/cdd.2015.93
19. Hayes JD, McLellan LI (1999) Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress. Free Rad Res 31:273–300
20. Hong SH et al (2017) Molecular crosstalk between ferroptosis and apoptosis: emerging role of ER stress-induced p53-independent. PUMA Exp Oncotarget 8:115164–115178. 10.18632/oncotarget.23046
21. Hou W et al (2016) Autophagy promotes ferroptosis by degradation of ferritin. Autophagy 12:1425–1428. 10.1080/15548627.2016.1187366
22. Hsu C, Shen YC, Cheng AL (2009) Sorafenib for the treatment of hepatocellular carcinoma across geographic regions. Expert Rev Clin Pharmacol 2:129–136. 10.1586/17512433.2.2.129
23. Jennis M et al (2016) An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. Genes Dev 30:918–930 10.1101/gad.275891.115
24. Kasukabe T, Honma Y, Okabe-Kado J, Higuchi Y, Kato N, Kumakura S (2016) Combined treatment with cotylenin A and phenethyl isothiocyanate induces strong antitumor activity mainly through the induction of ferroptotic cell death in human pancreatic cancer cells. Oncol Rep 36:968–976. 10.3892/or.2016.4867
25. Khan MR, Xiang S (2017) The p53-inducible long noncoding RNA TRINGS protects cancer cells from necrosis under glucose starvation. EMBO J 36:3483–3500. 10.15252/embj.201696239
26. Kinowaki Y et al (2018) Glutathione peroxidase 4 overexpression inhibits ROS-induced cell death in diffuse large B-cell lymphoma Laboratory investigation. J Tech Methods Pathol. 10.1038/s41374-017-0008-1
27. Knudsen ES, Knudsen KE (2008) Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer 8:714–724. 10.1038/nrc2401
28. Lachaier E et al (2014) Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors. Anticancer Res 34:6417–6422
29. Liu L et al (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66:11851–11858. 10.1158/0008-5472.can-06-1377
30. Liu J, Liu Y, Meng L, Liu K, Ji B (2017) Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma. Oncol Rep 38:899–907. 10.3892/or.2017.5722
31. Llovet JM et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390. 10.1056/NEJMoa0708857
32. Louandre C, Ezzoukhry Z, Godin C, Barbare JC, Maziere JC, Chauffert B, Galmiche A (2013) Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int J Cancer 133:1732–1742. 10.1002/ijc.28159
33. Louandre C et al (2015) The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells. Cancer Lett 356:971–977. 10.1016/j.canlet.2014.11.014
34. Ma Q (2013) Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol 53:401–426. 10.1146/annurev-pharmtox-011112-140320
35. Ma S, Henson ES, Chen Y, Gibson SB (2016) Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells. Cell Death Dis 7:e2307. 10.1038/cddis.2016.208
36. Mayhew CN et al (2007) RB loss abrogates cell cycle control and genome integrity to promote liver tumorigenesis. Gastroenterology 133:976–984. 10.1053/j.gastro.2007.06.025
37. Mrakovcic M, Frohlich LF (2018) p53-mediated molecular control of autophagy in tumor cells. Biomolecules. 10.3390/biom8020014
38. Ou W, Mulik RS, Anwar A, McDonald JG, He X, Corbin IR (2017) Low-density lipoprotein docosahexaenoic acid nanoparticles induce ferroptotic cell death in hepatocellular carcinoma. Free Rad Biol Med 112:597–607. 10.1016/j.freeradbiomed.2017.09.002
39. Shi X et al (2014) Nutlin-3 downregulates p53 phosphorylation on serine392 and induces apoptosis in hepatocellular carcinoma cells. BMB Rep 47:221–226
40. Shintoku R et al (2017) Lipoxygenase-mediated generation of lipid peroxides enhances ferroptosis induced by erastin and RSL3. Cancer Sci 108:2187–2194 10.1111/cas.13380
41. Sun X, Niu X, Chen R, He W, Chen D, Kang R, Tang D (2016a) Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis. Hepatology (Baltimore, Md) 64:488–500. 10.1002/hep.28574
42. Sun X, Ou Z, Chen R, Niu X, Chen D, Kang R, Tang D (2016b) Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology (Baltimore, Md) 63:173–184. 10.1002/hep.28251
43. Suzuki T, Motohashi H, Yamamoto M (2013) Toward clinical application of the Keap1-Nrf2 pathway. Trends Pharmacol Sci 34:340–346. 10.1016/j.tips.2013.04.005
44. Taira N, Nihira K, Yamaguchi T, Miki Y, Yoshida K (2007) DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to. DNA Damage Mol Cell 25:725–738. 10.1016/j.molcel.2007.02.007
45. Tonnus W, Linkermann A (2016) “Death is my Heir"—ferroptosis connects cancer pharmacogenomics and ischemia-reperfusion injury. Cell Chem Biol 23:202–203. 10.1016/j.chembiol.2016.02.005
46. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108. 10.3322/caac.21262
47. Wang XJ et al (2008) Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs the dark side of Nrf2. Carcinogenesis 29:1235–1243. 10.1093/carcin/bgn095
48. Wang D, Peng Y, Xie Y, Zhou B, Sun X, Kang R, Tang D (2016) Antiferroptotic activity of non-oxidative dopamine. Biochem Biophys Res Commun 480:602–607. 10.1016/j.bbrc.2016.10.099
49. Woo SM et al (2018) Corosolic acid induces non-apoptotic cell death through generation of lipid reactive oxygen species production in human renal carcinoma caki. Cells 19 10.3390/ijms19051309
50. Xie Y et al (2016) Identification of baicalein as a ferroptosis inhibitor by natural product library screening. Biochem Biophys Res Commun 473:775–780. 10.1016/j.bbrc.2016.03.052
51. Xie Y et al (2017) The Tumor Suppressor p53 Limits Ferroptosis by Blocking DPP4. Activity Cell Rep 20:1692–1704. 10.1016/j.celrep.2017.07.055
52. Yamaguchi Y, Kasukabe T, Kumakura S (2018) Piperlongumine rapidly induces the death of human pancreatic cancer cells mainly through the induction of ferroptosis. Int J Oncol 52:1011–1022. 10.3892/ijo.2018.4259
53. Yang WS et al (2014) Regulation of ferroptotic cancer cell death by GPX. 4 Cell 156:317–331. 10.1016/j.cell.2013.12.010
54. Yuan H, Li X, Zhang X, Kang R, Tang D (2016) CISD1 inhibits ferroptosis by protection against mitochondrial lipid peroxidation. Biochem Biophys Res Commun 478:838–844. 10.1016/j.bbrc.2016.08.034
55. Zhu S, Zhang Q, Sun X, Zeh HJ 3rd, Lotze MT, Kang R, Tang D (2017) HSPA5 regulates ferroptotic cell death in cancer cells. Cancer Res 77:2064–2077. 10.1158/0008-5472.can-16-1979